Disc Medicine Investor News: If You Have Suffered Losses in
The Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. (NASDAQ: IRON) after the FDA issued a Complete Response Letter regarding their bitopertin program, causing a 22% stock price drop. Investors who suffered losses are encouraged to contact the firm for potential class action participation to seek compensation. The firm highlights its track record in securities class actions.
Disc Medicine (IRON) Could Be 67% Undervalued On Its $30 Million Loan Reset
Disc Medicine (IRON) recently amended its loan agreement, securing $30 million and extending future access, which could positively impact investor perception of its cash runway and clinical plans. Despite being unprofitable with no reported revenue, analysts forecast a 64.2% annual revenue growth, leading to a P/B of 4.2x, suggesting investors see high potential. A discounted cash flow model suggests the stock might be significantly undervalued at its current price of $74.95, estimating a value of $225.46.
Did Disc Medicine’s Expanded Hercules Credit Access Just Shift IRON’s Funding Risk Profile?
Disc Medicine recently amended its loan agreement with Hercules Capital, immediately drawing US$30 million and gaining access to additional funds through mid-2028. This move enhances Disc Medicine's financial flexibility, potentially reducing near-term balance sheet pressure and dilution risk by enabling the company to fund operations without immediate reliance on equity markets. The expanded credit access supports its heme-focused pipeline and upcoming clinical trial readouts, particularly the APOLLO Phase 3 readout for bitopertin in Q4 2026.
Disc Medicine’s chief legal officer sells $187,500 in stock By Investing.com
Rahul Khara, Chief Legal Officer at Disc Medicine, Inc. (NASDAQ:IRON), sold 2,500 shares of company stock for $187,500 in late June after exercising stock options at a lower price. These transactions were executed under a Rule 10b5-1 trading plan. The biotech company's stock is currently trading at $73.09, resulting in a market cap of $2.8 billion, and, despite being unprofitable, has seen significant gains over the past year.
Form 4 Disc Medicine Inc For: 30 June By Investing.com
This article reports on a Form 4 filing for Disc Medicine Inc. for June 30. It's a brief financial markets update from Investing.com, typical of their reporting on corporate regulatory filings.
Disc Medicine COO Jonathan Yu sells $21,750 in company stock By Investing.com
Disc Medicine COO Jonathan Yu sold 300 shares of company stock worth $21,750 on June 26, 2026, after acquiring the same number of shares for $4,050, as part of a Rule 10b5-1 trading plan. The company's stock is currently trading at $73.09, up 38% over the past year, though InvestingPro analysis suggests it may be slightly overvalued despite a strong balance sheet. Disc Medicine also presented positive clinical trial data and is progressing with regulatory approvals for its investigational treatments.
Morgan Stanley Maintains Disc Medicine(IRON.US) With Buy Rating, Raises Target Price to $85
Morgan Stanley has reiterated its "Buy" rating for Disc Medicine (IRON.US) and increased its target price to $85. This update suggests a continued positive outlook from the financial firm on the company's prospects. Investors may view this as a bullish signal for Disc Medicine's stock.
Disc Medicine’s chief legal officer sells $187,500 in stock
Disc Medicine's Chief Legal Officer, Rahul Khara, sold 2,500 shares of company stock for $187,500 in late June, following the exercise of stock options for an equivalent number of shares. These transactions were executed under a Rule 10b5-1 trading plan. The company's stock is currently trading at $73.09, with analysts maintaining an optimistic outlook despite the stock appearing overvalued according to InvestingPro analysis.
Disc Medicine COO Jonathan Yu sells $21,750 in company stock By Investing.com
Jonathan Yen-Wen Yu, COO of Disc Medicine Inc., sold 300 shares of company stock for $21,750 on June 26, 2026, after acquiring the same number of shares earlier that day. This transaction was part of a Rule 10b5-1 trading plan. The company remains unprofitable despite a 38% stock increase over the past year, with ongoing advancements in clinical trials and regulatory discussions for its investigational treatments.
Disc Medicine COO Jonathan Yu sells $21,750 in company stock By Investing.com
Jonathan Yen-Wen Yu, COO of Disc Medicine Inc., sold 300 shares of company stock for $21,750 on June 26, 2026, after acquiring the same number of shares for $4,050. These transactions were part of a Rule 10b5-1 trading plan. The company's stock currently trades at $73.09, showing an uptick over the past year, though InvestingPro analysis suggests it might be overvalued despite a strong balance sheet.
Disc Medicine (NASDAQ: IRON) CLO exercises options, sells 2,500 common shares
Disc Medicine's Chief Legal Officer, Rahul Khara, exercised stock options for 2,500 common shares at $14.69 per share and subsequently sold all 2,500 shares at $75.00 per share. These transactions, executed under a pre-planned Rule 10b5-1 trading plan, resulted in a net sale of 2,500 shares valued at $187,500. After these trades, Khara directly holds 52,173 common shares, maintaining a significant stake in the company.
Disc Medicine’s chief legal officer sells $187,500 in stock By Investing.com
Rahul Khara, Chief Legal Officer at Disc Medicine, Inc., sold 2,500 shares of the company's common stock for $187,500 in late June, following the exercise of stock options for an equivalent number of shares. The transactions were conducted under a Rule 10b5-1 trading plan, leaving Mr. Khara with 52,173 shares. While the stock is considered overvalued by InvestingPro, analysts remain optimistic with price targets between $79 and $128, and the company recently presented positive clinical trial data for its investigational treatments.
Disc Medicine (NASDAQ: IRON) extends Hercules loan access and covenants
Disc Medicine (NASDAQ: IRON) has amended its existing Loan and Security Agreement with Hercules Capital, extending access to debt financing and adjusting covenant timing. The company will immediately draw $30 million, and a $50 million tranche has been restructured into two $25 million tranches with extended availability. The amendment also pushes back the initial testing date for the minimum cash covenant to July 1, 2028, providing the company with longer access to capital and more flexible compliance terms.
Disc Medicine - Enters First Amendment To Loan Agreement On June 25, 2026 - SEC Filing
Disc Medicine has entered into a first amendment to its loan agreement on June 25, 2026. This information was disclosed in an SEC filing. The news was reported by Reuters via Refinitiv.
Disc Medicine (NASDAQ: IRON) COO exercises options and sells 300 shares
Disc Medicine's COO, Jonathan Yu, reported a pre-planned insider transaction. On June 26, 2026, Yu exercised stock options to acquire 300 shares at $13.50 per share and subsequently sold these 300 shares in an open-market transaction at an average price of $72.50 per share. This transaction was conducted under a Rule 10b5-1 trading plan adopted on March 17, 2026, indicating it was scheduled in advance.
Disc Medicine COO Jonathan Yu sells $21,750 in company stock By Investing.com
Jonathan Yen-Wen Yu, COO of Disc Medicine Inc. (NASDAQ: IRON), sold 300 shares of company stock for $21,750 on June 26, 2026, after acquiring them for $4,050, as part of a Rule 10b5-1 trading plan. Following these transactions, Yu directly holds 54,324 shares. The company's stock is up 38% over the past year, and Disc Medicine recently presented updated clinical trial data and is engaging with the FDA regarding regulatory pathways for its treatments.
Price to sales forward of Disc Medicine, Inc. – NASDAQ:IRON
This article provides the "Price to sales forward" metric for Disc Medicine, Inc. (NASDAQ: IRON) directly from TradingView. The content is concise, focusing solely on this financial data point for the specified company. It notes that the market is currently closed with no trades.
Price to book forward of Disc Medicine, Inc. – NASDAQ:IRON
The article focuses on the "Price to book forward" financial metric for Disc Medicine, Inc., traded on NASDAQ under the symbol IRON. It appears to be a financial data page from TradingView, providing an overview of the company's financial performance. The content indicates that the market is currently closed for this stock.
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON
The Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. (NASDAQ: IRON) after the FDA issued a Complete Response Letter for its bitopertin drug, causing a 22% stock drop. Investors who purchased Disc Medicine securities are encouraged to contact the firm to inquire about a prospective class action to recover losses. The firm highlights its experience and success in securities class action litigation.
Disc Medicine Investor News: If You Have Suffered Losses in
The Rosen Law Firm is investigating potential securities claims on behalf of investors who suffered losses in Disc Medicine, Inc. (NASDAQ: IRON). This investigation follows a 22% stock price drop after the FDA issued a Complete Response Letter for Disc Medicine's bitopertin program due to uncertainties in the New Drug Application. The firm encourages affected shareholders to contact them regarding a prospective class action to recover investor losses.
Form 144 Disc Medicine For: 26 June By Investing.com
This article announces the filing of Form 144 for Disc Medicine on June 26. It is a brief financial update from Investing.com. The content provided is minimal, primarily serving as a headline for a regulatory filing.
IRON (NASDAQ: IRON) notice: proposed 2,500-share option sale; prior 7,500-share 10b5-1
A Form 144 filing for Disc Medicine, Inc. (NASDAQ: IRON) indicates a proposed sale of 2,500 common shares through an option exercise on June 26, 2026. This filing also discloses previous 10b5-1 sales by Rahul Khara of 7,500 shares on June 18, 2026, totaling $526,660.50. Morgan Stanley Smith Barney LLC is listed as the broker.
Disc Medicine, Inc. Actuals & Estimates (NASDAQ:IRON)
This article provides an overview of Disc Medicine, Inc. (NASDAQ: IRON) stock, including its current price, historical performance, analyst forecasts, and financial figures. It details past earnings and revenue, market capitalization, and answers frequently asked questions about the company's stock. The article also provides key dates like the next earnings report.
Form 4 Disc Medicine Inc For: 24 June By Investing.com
This article announces the filing of Form 4 for Disc Medicine Inc. for the date of June 24, as reported by Investing.com. It is a brief administrative notice indicating a corporate insider transaction filing. The content itself is very short, primarily serving as a title and a link to more information about the filing.
Disc Medicine COO Jonathan Yu sells $704,795 of iron common stock
Disc Medicine COO Jonathan Yu recently sold 9,700 shares of the company's common stock for $704,795, executing a Rule 10b5-1 trading plan. This sale followed his acquisition of the same number of shares through stock option exercises. Yu maintains a significant direct and derivative holding in Disc Medicine.
Disc Medicine Investor News: If You Have Suffered Losses in
The Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. (NASDAQ: IRON) after its stock price fell 22% due to a Complete Response Letter from the FDA regarding its bitopertin program. Shareholders who suffered losses are encouraged to contact the law firm to potentially join a class action lawsuit seeking compensation. The FDA cited uncertainties in Disc Medicine's new drug application that required additional evidence.
Disc Medicine COO Jonathan Yu sells $704,795 of iron common stock
Jonathan Yu, COO of Disc Medicine, Inc., sold 9,700 shares of common stock for over $704,000 on June 22, 2026, as part of a pre-planned trading strategy. This sale followed his exercise of stock options at a lower price on the same day. The stock has seen significant returns over the past year but is considered volatile and potentially overvalued.
Form 4 Disc Medicine Inc For: 24 June By Investing.com
This article reports on a Form 4 filing for Disc Medicine Inc. on June 24, as updated by Investing.com. It indicates that the filing is related to the company IRON, with a stock symbol -0.11%. The document provides no further details on the content of the Form 4.
Disc Medicine (NASDAQ: IRON) COO exercises options, sells 9,700 shares under 10b5-1 plan
Disc Medicine, Inc.'s Chief Operating Officer, Jonathan Yu Yen-Wen, recently executed an options-related transaction. He exercised stock options to acquire 9,700 shares at $13.50 per share and subsequently sold all 9,700 shares on the open market at a weighted average price of $72.6593 per share. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on March 17, 2026, and he now directly holds 54,324 shares and 24,147 stock options.
Disc Medicine CLO Rahul Khara sells $526,660 in company stock
Rahul Khara, CLO of Disc Medicine, Inc. (NASDAQ:IRON), sold 7,500 shares of company stock for a total of $526,660 on June 18, 2026. This transaction followed the exercise of stock options for the same number of shares and was executed under a Rule 10b5-1 trading plan. After these transactions, Khara directly holds 52,173 shares, with the company's stock showing significant volatility and trading up 28% over the past year.
Disc Medicine (NASDAQ: IRON) investors re-elect directors and ratify Ernst & Young
Disc Medicine, Inc. (NASDAQ: IRON) held its 2026 annual meeting where shareholders re-elected three Class III directors—Donald Nicholson, Ph.D., John Quisel, J.D., Ph.D., and William White, M.P.P., J.D.—for three-year terms. Additionally, stockholders approved, on a non-binding advisory basis, the compensation for named executive officers and ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the 2026 fiscal year. These actions affirm the company's current governance and audit practices.
Director at Disc Medicine (NASDAQ: IRON) granted 6,212 stock options at $70.79
Disc Medicine director Kevin Bitterman was granted 6,212 stock options with an exercise price of $70.79 per share, expiring on June 17, 2036. The options vest upon the company's 2027 annual stockholders' meeting or one year from the grant date, subject to his continued service. Proceeds from the sale of shares upon exercise will be transferred to Atlas Venture Life Science Advisors, LLC, and Bitterman disclaims ownership except for any pecuniary interest.
Disc Medicine CLO Rahul Khara sells $526,660 in company stock By Investing.com
Rahul Khara, Disc Medicine's Chief Legal Officer, sold 7,500 shares of company stock for $526,660 on June 18, 2026, after exercising stock options. These transactions were executed under a Rule 10b5-1 trading plan and occurred amidst recent volatility in IRON shares, which are up 28% over the past year. Khara now directly holds 52,173 shares of Disc Medicine.
Disc Medicine CLO Rahul Khara sells $526,660 in company stock
Rahul Khara, CLO at Disc Medicine, Inc. (NASDAQ:IRON), sold 7,500 shares of company stock worth $526,660 on June 18, 2026, after exercising stock options. The sales occurred through a Rule 10b5-1 trading plan. Despite recent volatility, IRON shares are up 28% over the past year.
Disc Medicine (NASDAQ: IRON) CEO trades 34K shares under Rule 10b5-1 plan
Disc Medicine, Inc.'s CEO, John D. Quisel, reported exercising 34,000 stock options and simultaneously selling 34,000 shares of common stock between $69.35 and $71.85 per share under a pre-arranged Rule 10b5-1 trading plan. After these transactions, Quisel directly holds 226,064 shares and 41,375 stock options. The net effect was a sale of 34,000 shares, but his overall equity stake remains significant.
Disc Medicine (NASDAQ: IRON) legal chief exercises options, sells 7,500 shares
Rahul Khara, Disc Medicine's Chief Legal Officer, exercised stock options to acquire 7,500 shares at $14.69 each and subsequently sold all 7,500 shares in open-market transactions at prices ranging from $69.35 to $71.81. These transactions, executed on June 18, 2026, were performed under a pre-arranged Rule 10b5-1 trading plan. Following these sales, Khara directly holds 59,673 shares of Disc Medicine common stock.
Form 4 Disc Medicine Inc For: 23 June By Investing.com
This article from Investing.com reports on a Form 4 filing for Disc Medicine Inc. dated June 23. The content primarily consists of market data, indices, and popular news headlines, indicating a standard financial news update with minimal specific details about the Form 4 itself.
Disc Medicine (NASDAQ: IRON) director receives grant of 6,212 stock options
Disc Medicine, Inc. director Donald William Nicholson was granted 6,212 stock options with an exercise price of $70.79 per share, expiring on June 17, 2036. These options will vest upon the earlier of the company's 2027 annual stockholder meeting or the one-year anniversary of the grant date, provided Nicholson continues his service. This transaction is classified as a grant or award acquisition, reflecting compensation rather than a market trade.
Disc Medicine (NASDAQ: IRON) director receives grant of 6,212 stock options
Disc Medicine, Inc. director Georges Gemayel was granted 6,212 stock options with an exercise price of $70.79 per share, expiring on June 17, 2036. These options will vest on the earlier of the company's 2027 annual stockholder meeting or the one-year anniversary of the grant date, provided he continues his directorship. This transaction is a compensation award and not an open-market purchase or sale.
Form 4 Disc Medicine Inc For: 23 June By Investing.com
This article from Investing.com reports on a Form 4 filing for Disc Medicine Inc. dated June 23rd. Form 4 filings disclose changes in beneficial ownership of a company's securities by insiders. No specific details about the filing are provided in the snippet.
Disc Medicine (NASDAQ: IRON) director granted 6,212 stock options at $70.79 strike
Disc Medicine director Mark Chin has been granted 6,212 stock options at an exercise price of $70.79 per share, expiring on June 17, 2036. This grant serves as compensation, with no upfront purchase cost. The options will vest either at the company's 2027 annual shareholder meeting or one year from the grant date, provided Chin remains a director.
Disc Medicine (IRON) grants director Liam Ratcliffe 6,212 stock options
Disc Medicine, Inc. director Liam Ratcliffe was granted 6,212 stock options with an exercise price of $70.79 per share, expiring on June 17, 2036. These options will vest on the earlier of the company's 2027 annual stockholder meeting or the one-year anniversary of the grant date, provided he continues his service. This grant is a compensation-related award rather than an open-market transaction.
Jonathan Yu proposes sale of 10,000 IRON shares (NASDAQ: IRON)
Jonathan Yu has proposed the sale of 10,000 shares of Disc Medicine, Inc. (NASDAQ: IRON) common stock, tied to an exercise of stock options, scheduled for June 22, 2026. This Form 144 filing also discloses a previous 10b5-1 sale by Yu of 18,612 shares on June 16, 2026, which generated $1,287,800.28. The filing is considered a routine insider sale disclosure with a neutral impact and sentiment.
Disc Medicine (Nasdaq:IRON) - Stock Analysis
Disc Medicine (Nasdaq:IRON) is a clinical-stage biopharmaceutical company focused on hematologic diseases, with a market cap of US$2.7 billion and an analyst price target suggesting it is 30.3% undervalued. The company recently released updated positive clinical data for its DISC-0974 and bitopertin programs, though bitopertin is also under FDA review and legal investigation following a Complete Response Letter in February 2026. Despite potential risks related to insider stock sales and past share volatility, Disc Medicine maintains a solid cash runway into 2029.
Disc Medicine Investor News: If You Have Suffered Losses in
The Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. (NASDAQ: IRON) following allegations of misleading business information. This investigation comes after the FDA issued a Complete Response Letter for Disc Medicine's bitopertin program on February 13, 2026, causing a 22% stock price drop. Investors who have suffered losses are encouraged to contact the firm for potential compensation through a class action lawsuit.
Disc Medicine Investor News: If You Have Suffered Losses in
The Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. (NASDAQ: IRON) after the FDA issued a Complete Response Letter for its bitopertin program, causing a 22% stock price drop. Investors who suffered losses are encouraged to contact the firm for a potential class action lawsuit. The firm highlights its experience and success in securities class action litigation.
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON
The Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. (NASDAQ: IRON) after the company received a Complete Response Letter from the FDA for its bitopertin program, leading to a 22% stock price drop on February 13, 2026. The firm encourages investors who purchased Disc Medicine securities to inquire about joining a prospective class action to recover investor losses. The investigation focuses on alleged materially misleading business information issued by Disc Medicine.
Disc Medicine Investor News: If You Have Suffered Losses in
The Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. (NASDAQ: IRON) after the FDA issued a Complete Response Letter for its bitopertin program, causing Disc Medicine's stock to fall 22%. Investors who suffered losses are encouraged to contact the firm to join a prospective class action lawsuit. The firm emphasizes its track record in securities class actions.
[144] Disc Medicine, Inc. SEC Filing
This SEC filing (Form 144) for Disc Medicine, Inc. (IRON) details a proposed sale of 7,500 shares of common stock by an insider, valued at $526,575. The securities were acquired through the exercise of stock options on June 18, 2026. The filing indicates a neutral impact and sentiment regarding this transaction.
Disc Medicine (NASDAQ: IRON) COO exercises options, sells 18,612 shares
Disc Medicine's COO, Yu Jonathan Yen-Wen, exercised stock options for 18,612 shares and subsequently sold all of them on June 16, 2026. The shares were sold at weighted average prices ranging from approximately $68.76 to $69.92 per share, and these transactions were conducted under a pre-arranged Rule 10b5-1 trading plan. The total value of the shares sold amounted to $1.29 million.
